BR112013030456A2 - composição farmacêutica compreendendo derivado de amida inibindo o crescimento de células de câncer e lubrificante de sal não-metálico - Google Patents

composição farmacêutica compreendendo derivado de amida inibindo o crescimento de células de câncer e lubrificante de sal não-metálico

Info

Publication number
BR112013030456A2
BR112013030456A2 BR112013030456A BR112013030456A BR112013030456A2 BR 112013030456 A2 BR112013030456 A2 BR 112013030456A2 BR 112013030456 A BR112013030456 A BR 112013030456A BR 112013030456 A BR112013030456 A BR 112013030456A BR 112013030456 A2 BR112013030456 A2 BR 112013030456A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
cancer cell
cell growth
amide derivative
metallic salt
Prior art date
Application number
BR112013030456A
Other languages
English (en)
Other versions
BR112013030456B1 (pt
Inventor
Jae Hyun Park
Jin Cheul Kim
Jong Soo Woo
Kyeong Soo Kim
Yo Han Kim
Yong Il Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of BR112013030456A2 publication Critical patent/BR112013030456A2/pt
Publication of BR112013030456B1 publication Critical patent/BR112013030456B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/604—Polycarboxylic acid esters, the acid moiety containing more than two carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Abstract

resumo “composição farmacêutica compreendendo derivado de amida inibindo o crescimento de células de câncer e lubrificante de sal não-metálico” descrita é uma composição farmacêutica compreendendo um derivado de amida ou um sal farmaceuticamente aceitável do mesmo e um lubrificante de sal não metálico, que pode ser usado como um inibidor de crescimento de célula de câncer eficaz devido a sua estabilidade de armazenamento realçada sem mudanças de qualidade com o passar do tempo.
BR112013030456-1A 2011-06-07 2012-05-18 Composição farmacêutica compreendendo pozitinib e lubrificante de sal não metálico, método para preparar uma formulação da dita composição e método para estabilizar a dita composição BR112013030456B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2011-0054685 2011-06-07
KR1020110054685A KR101317809B1 (ko) 2011-06-07 2011-06-07 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
PCT/KR2012/003970 WO2012169733A1 (en) 2011-06-07 2012-05-18 Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant

Publications (2)

Publication Number Publication Date
BR112013030456A2 true BR112013030456A2 (pt) 2016-09-27
BR112013030456B1 BR112013030456B1 (pt) 2022-08-02

Family

ID=47296259

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013030456-1A BR112013030456B1 (pt) 2011-06-07 2012-05-18 Composição farmacêutica compreendendo pozitinib e lubrificante de sal não metálico, método para preparar uma formulação da dita composição e método para estabilizar a dita composição

Country Status (25)

Country Link
US (2) US9731022B2 (pt)
EP (1) EP2718282B1 (pt)
JP (1) JP6030643B2 (pt)
KR (1) KR101317809B1 (pt)
CN (1) CN103596940B (pt)
AR (1) AR086851A1 (pt)
AU (1) AU2012267642C1 (pt)
BR (1) BR112013030456B1 (pt)
CA (2) CA3053181A1 (pt)
CL (1) CL2013003513A1 (pt)
CO (1) CO6852070A2 (pt)
DK (1) DK2718282T3 (pt)
EC (1) ECSP14013121A (pt)
ES (1) ES2625268T3 (pt)
IL (1) IL229739B (pt)
MA (1) MA35405B1 (pt)
MX (2) MX361129B (pt)
MY (1) MY166949A (pt)
PE (1) PE20141040A1 (pt)
PT (1) PT2718282T (pt)
RU (1) RU2632099C2 (pt)
TW (1) TWI617307B (pt)
UA (1) UA112545C2 (pt)
WO (1) WO2012169733A1 (pt)
ZA (1) ZA201400051B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
EP2878453A1 (de) 2013-11-28 2015-06-03 Authentic Vision GmbH Objektmarkierung zur optischen Authentifizierung und Verfahren zu deren Herstellung
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
KR101669240B1 (ko) * 2015-03-12 2016-10-25 아주대학교산학협력단 테노포비어 디소프록실 유리염기를 포함하는 정제 및 이의 제조방법
JP6585193B2 (ja) * 2015-12-28 2019-10-02 沢井製薬株式会社 ゲフィチニブ含有錠剤
CN108057036B (zh) * 2016-11-07 2023-06-13 正大天晴药业集团股份有限公司 一种egfr抑制剂的固体药物组合物
AU2017363199B2 (en) 2016-11-17 2023-08-17 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations
EP3773551A4 (en) * 2018-03-27 2022-03-23 Board of Regents, The University of Texas System COMPOUNDS WITH ANTITUMOR ACTIVITY AGAINST CANCER CELLS CARRYING HER2 EXON 19 MUTATIONS
WO2020053816A1 (en) * 2018-09-14 2020-03-19 Hanmi Pharmaceutical Co., Ltd. Crystalline forms of a quinazole compound and its hydrochloride salts
JP2022527499A (ja) * 2019-03-29 2022-06-02 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｈｅｒ２エクソン２１挿入を有するがん細胞に対する抗腫瘍活性を有する化合物
KR102254307B1 (ko) * 2019-04-03 2021-05-21 위더스제약주식회사 보관 안정성이 향상된 에페리손 약제학적 조성물
US20220378790A1 (en) * 2019-10-24 2022-12-01 Hanmi Pharm Co., Ltd. Pharmaceutical preparation comprising an amide derivative inhibiting the growth of cancer cell and a pharmaceutical product containing the same

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02275891A (ja) * 1988-12-29 1990-11-09 Tsumura & Co 新規な複核白金錯体および該錯体を有効成分とする抗腫瘍剤
ATE227574T1 (de) 1994-08-23 2002-11-15 Smithkline Beecham Plc Verbesserte,ibuprofen und codein enthaltende, pharmazeutische zusammensetzungen
KR980008219A (ko) 1996-07-16 1998-04-30 김상응 안정화된 주사제용 약제학적 조성물
KR980008219U (ko) 1996-07-31 1998-04-30 배순훈 세탁기의 구동모터 냉각팬
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
JP3687025B2 (ja) * 1998-06-04 2005-08-24 東和薬品株式会社 安定なマレイン酸エナラプリル錠剤
WO2001021596A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
DE10042061A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EA009300B1 (ru) 2002-03-30 2007-12-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг 4-(n-фениламино)хиназолины/-хинолины в качестве ингибиторов тирозинкиназы
CN1882570B (zh) 2003-09-19 2010-12-08 阿斯利康(瑞典)有限公司 喹唑啉衍生物
BRPI0414735A (pt) 2003-09-25 2006-11-21 Astrazeneca Ab derivado de quinazolina, composto, composição farmacêutica, uso de derivado de quinazolina, método para produzir um efeito anti-proliferativo em um animal de sangue quente, e, processo para a preparação de um derivado de quinazolina
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
DE10345875A1 (de) 2003-09-30 2005-04-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Vewendung und Verfahren zu ihrer Herstellung
CA2560286A1 (en) 2004-03-23 2005-09-29 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
KR20050104152A (ko) 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
EP1919900A2 (de) 2005-08-22 2008-05-14 Boehringer Ingelheim International Gmbh Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
BRPI0619603A2 (pt) 2005-12-12 2011-10-11 Boehringer Ingelheim Int heterociclos bicìclicos, sais fisiologicamante compatìveis, medicamentos que contêm esses compostos, bem como uso e processos para produção dos heterociclos bicìclicos
DK1847258T4 (da) 2006-04-13 2013-04-15 Acino Pharma Ag Partialglycerider som smøremiddel til farmaceutiske sammensætninger indeholdende thieno[3,2-c]pyridin-derivater
US8937181B2 (en) 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
US20100178340A1 (en) 2007-06-22 2010-07-15 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
MY144136A (en) 2009-04-20 2011-08-10 Univ Sains Malaysia Throttle and brake lock
AU2010273319B2 (en) * 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
CN102822676B (zh) * 2010-01-12 2015-02-18 雀巢产品技术援助有限公司 用于预测三阴性乳腺癌对疗法的应答的方法
KR101217526B1 (ko) 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR101272613B1 (ko) 2011-10-05 2013-06-10 한미사이언스 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체

Also Published As

Publication number Publication date
KR20120135777A (ko) 2012-12-17
ES2625268T3 (es) 2017-07-19
MX2013013997A (es) 2014-06-23
MY166949A (en) 2018-07-25
KR101317809B1 (ko) 2013-10-16
WO2012169733A1 (en) 2012-12-13
TW201302201A (zh) 2013-01-16
CN103596940B (zh) 2017-09-12
RU2013158858A (ru) 2015-07-20
US20140112962A1 (en) 2014-04-24
JP2014516082A (ja) 2014-07-07
BR112013030456B1 (pt) 2022-08-02
CA3053181A1 (en) 2012-12-13
CN103596940A (zh) 2014-02-19
PE20141040A1 (es) 2014-09-08
AU2012267642A1 (en) 2014-01-30
CA2837703A1 (en) 2012-12-13
MA35405B1 (fr) 2014-09-01
IL229739B (en) 2018-01-31
US9931406B2 (en) 2018-04-03
AU2012267642C1 (en) 2017-11-16
AR086851A1 (es) 2014-01-29
MX361129B (es) 2018-11-28
UA112545C2 (uk) 2016-09-26
CA2837703C (en) 2019-09-24
PT2718282T (pt) 2017-05-25
US20170340744A1 (en) 2017-11-30
EP2718282B1 (en) 2017-03-15
JP6030643B2 (ja) 2016-11-24
DK2718282T3 (en) 2017-05-22
RU2632099C2 (ru) 2017-10-02
NZ619606A (en) 2015-07-31
IL229739A0 (en) 2014-01-30
MX2021005494A (es) 2022-06-08
AU2012267642B2 (en) 2017-04-20
TWI617307B (zh) 2018-03-11
CO6852070A2 (es) 2014-01-30
ZA201400051B (en) 2015-04-29
EP2718282A1 (en) 2014-04-16
ECSP14013121A (es) 2014-02-28
CL2013003513A1 (es) 2014-09-26
US9731022B2 (en) 2017-08-15
EP2718282A4 (en) 2015-04-15

Similar Documents

Publication Publication Date Title
BR112013030456A2 (pt) composição farmacêutica compreendendo derivado de amida inibindo o crescimento de células de câncer e lubrificante de sal não-metálico
BR112012031510A2 (pt) composição farmacêutica compreendendo derivado de amida ou um sal deste farmaceuticamente aceitável
EA201291309A1 (ru) ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ, sGC АКТИВАТОРОВ, ОДНИХ И В КОМБИНАЦИИ С PDE5 ИНГИБИТОРАМИ, ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОГО СКЛЕРОЗА (SSc)
EA201200390A1 (ru) Макроциклические ингибиторы сериновых протеаз гепатита с
MX2012011504A (es) Inhibidores de enzima 1 dependiente de inositol (ire-1 alfa).
MX2013004733A (es) Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
MX2015012028A (es) Inhibidores de la ruta de quinurenina.
BR112015002821A8 (pt) compostos inibidores de neprilisina, composição farmacêutica e uso dos compostos
EA201390347A1 (ru) Лечение заболеваний
AR087107A1 (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
MX2013004491A (es) Boronatos como inhibidores de arginasa.
CL2012002318A1 (es) Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer.
AR084433A1 (es) Inhibidores de la faah y composiciones farmaceuticas que los contienen
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
MX350666B (es) Composiciones y sus usos para tratar hiperuricemia y trastornos metabolicos asociados con hiperuricemia.
MX348860B (es) Derivados de pirazoloespirocetona para usarse como inhibidores de acetil-coa carboxilasa.
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
TW200716653A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
MY146803A (en) Benzothiazol-2-on derivatives as lipase and phospholipase inhibitors
EA201100350A1 (ru) Противогрибковые средства
MX2014006088A (es) Biomarcadores para canceres que responden a moduladores de la actividad de hec1.
AR088735A1 (es) Compuestos de tienopirimidina que son inhibidores de canal de potasio
EA201390757A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПРОИЗВОДСТВА
EA201591487A1 (ru) Производные замещенной бисфенилбутановой кислоты в качестве ингибиторов nep с улучшенной in vivo эффективностью

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/05/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.